Company intelligence / Profile preview

Hangzhou Adamerck Pharmlabs Inc.

Hangzhou, Zhejiang, Chinaadamerck.net ↗

Ownership: Private
Development stage: Preclinical

Overview

Hangzhou Adamerck Pharmlabs Inc. specializes in the research and development of innovative small molecule pharmaceuticals with over ten proprietary drugs addressing global medical needs. Their lead asset, Adamgammadex Sodium for reversal of neuromuscular blockade, has reached NDA submission in China with positive Phase III results presented at WCA2024. Other pipeline assets target cardiovascular/cerebrovascular diseases and infectious disease.

Therapeutic areas: OtherCardiovascularOncologyInfectious Diseases
Modalities: Small moleculesNovel patented pharmaceuticals
Industry: Biotech

Drug pipeline

5 assets

adamgammadex

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hangzhou Adamerck Pharmlabs Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Adamerck Pharmlabs Inc..

Explore the full profile